Reduced U snRNP assembly causes
motor axon degeneration animal
model spinal muscular atrophy
Christoph Winkler,2,5 Christian Eggert,1,5 Dietmar Gradl,3,5 Gunter Meister,4 Marieke Giegerich,2
Doris Wedlich,3 Bernhard Laggerbauer,1 Utz Fischer1,6
1
 Institute Biochemistry 2Institute Physiological Chemistry, Biocenter University WÃ¼rzburg, D-97074
WÃ¼rzburg, Germany; 3Institute Zoology II, University Karlsruhe, D-76131 Karlsruhe, Germany; 4Max-Planck-Institute Biochemistry, D-82152 Martinsried, Germany


Spinal muscular atrophy (SMA) motoneuron disease caused reduced levels survival motoneuron
(SMN) protein. Previous studies assigned SMN uridine-rich small nuclear ribonucleoprotein particle (U
snRNP) assembly, splicing, transcription, RNA localization.  used gene silencing assess effect SMN protein deficiency U snRNP metabolism living cells organisms. HeLa cells, reduction SMN levels SMA patients impairs U snRNP assembly. line 
induced silencing SMN expression Xenopus laevis zebrafish arrested embryonic development. severe knock conditions, zebrafish embryos proceeded development exhibited dramatic
SMA-like motor axon degeneration. observed silencing essential factors U snRNP assembly pathway, Gemin2 pICln. Importantly, injection purified U snRNPs SMN- Gemin2-deficient embryos Xenopus zebrafish prevented developmental arrest motoneuron
degeneration, respectively. findings suggest motoneuron degeneration SMA patients direct
consequence impaired production U snRNPs.
[Keywords: Survival motor neurons (SMN); U snRNP assembly; motoneuron; spinal muscular atrophy;
zebrafish]
Supplemental material available http://www.genesdev.org.
Received March 1, 2005; revised version accepted July 27, 2005.




Spinal muscular atrophy (SMA) hereditary neuro-                      nario, showing induced reduction SMN protein
muscular disease caused reduced levels survival                 levels leads motoneuron defects (Hsieh-Li et al. 2000;
motoneuron (SMN) protein (Lefebvre et al. 1995). hu-                   Monani et al. 2000; Jablonka et al. 2002; McWhorter et
mans, SMN protein encoded iden-                      al. 2003). Opposed SMN protein insufficiency, com-
tical gene copies, SMN1 SMN2. healthy                     plete lack SMN protein patients affected individuals, small amounts functional                    reported  homozygous inactivation SMN SMN protein expressed SMN2, al-                       mice causes embryonic death, presumed teration splice regulatory sequence exon 7 (Lorson                lethal humans.
et al. 1999; Lorson Androphy 2000; Cartegni                          tissue-specific degeneration cells caused Krainer 2002; Kashima Manley 2003). expres-                       SMN protein deficiency puzzling, given SMN sion functional SMN protein largely depends                  expressed ubiquitously restricted moto- SMN1. pathogenic mutations identified far                      neurons. solve paradox, experimental ap-
map copy gene result reduced ex-                    proaches exploited assign SMN specific
pression functional SMN protein. widely ac-                     function. studies revealed links SMN cepted causes degeneration â?£-mo-                   assembly spliceosomal histone mRNA-pro-
toneurons spinal cord muscular atrophy                     cessing uridine-rich small nuclear ribonucleoprotein par-
symptomatic SMA.  recent studies carried                   ticles (U snRNPs) (Meister Fischer 2002; Pillai et al. mice zebrafish elegantly recapitulated sce-                   2003; Gubitz et al. 2004), pre-mRNA splicing catalysis
                                                                          (Pellizzoni et al. 1998; Meister et al. 2000), axonal
5
 authors contributed equally work.
                                                                          transport (Jablonka et al. 2001; Rossoll et al. 2003; Zhang
6
 Corresponding author.                                                    et al. 2003), transcription (Strasswimmer et al.
E-MAIL utz.fischer@biozentrum.uni-wuerzburg  FAX 49-931-888-           1999).
4028.
Article publication http://www.genesdev.org/cgi/doi/10.1101/      function understood gad.342005.                                                               SMNâ€™s contribution assembly spliceosomal


2320       GENES & DEVELOPMENT 19:2320â€“2330 Â© 2005 Cold Spring Harbor Laboratory Press ISSN 0890-9369/05; www.genesdev.org
                                                                                         RNP assembly spinal muscular atrophy



U snRNPs U1, U2, U4, U5. key step forma-        2001a; Meister Fischer 2002; Pellizzoni et al. 2002),
tion particles takes place cytosol,    focused site-specific inactivation SMN (Pell-
seven called Sm-proteins common         izzoni et al. 1998; Grimmler et al. 2005). snRNPs associate U snRNA (U1, U2, U4, U5,          experiments, learned SMN complex essen-
respectively) stable, ring-shaped structure (Kambach    tial U snRNP assembly. Nonetheless, unclear
et al. 1999). functional state U snRNP           U snRNP assembly likewise impaired achieved additional, particle-specific, proteins   patients   conferred moto-
bound Sm core particle. Ultimately, cap struc-   neuron defects associated SMA phenotype. tures U snRNAs undergo hypermethylation,          mentioned  patients, suffering resulting U snRNPs imported nucleus,        severe form SMA (type SMA), express SMN function splicing  Luhrmann           extent, levels functional SMN protein
2001). formation Sm core occur       amounting 30 â€“40  normal level (Lefebvre
spontaneously vitro, shown     et al. 1997).  asked extent requires activity SMN test reca-     SMN protein reduction affected U snRNP assembly
pitulates vivo conditions (Meister et al. 2001a; Meis-     approach analyze U
ter Fischer 2002; Pellizzoni et al. 2002). SMN oper-     snRNP assembly primary cells patients, using
ates functional entity termed SMN complex,          assay described previously (Meister et al. major protein components grouped          2001a). opposed HeLa cells Xenopus egg extract,
Gemins 2â€“7, factor termed unrip (Meister            did succeed preparing active extracts,
Fischer 2002; Gubitz et al. 2004). Immunodepletion        cells patient origin unaffected
cell extracts showed entity essential U     individuals. decided elaborate experi-
snRNP assembly. Furthermore, purified SMN complex            mental conditions HeLa cells reflect shown sufficient transfer Sm      reduced SMN expression observed patients.
proteins U snRNAs (Meister Fischer 2002; Pell-         approach, tested tissue culture izzoni et al. 2002). Nonetheless, activity SMN    RNA interference (RNAi) suitable adjusting
complex greatly enhanced interac-        SMN expression levels observed patients. Pri-
tion second entity termed PRMT5 complex (Meis-        mary fibroblasts type SMA patients used ter Fischer 2002). addition eponym, type   standard pathogenic conditions. Compared fi-
II arginine methyltransferase PRMT5, complex        broblasts unaffected individuals, expression tains Sm protein-binding factor pICln WD         endogenous SMN protein cells reduced repeat protein WD45/MEP50 (Branscombe et al. 2001;           23  normal level (Fig. 1A [cf. lanes 1,2 3,4], B).
Friesen et al. 2001; Meister et al. 2001b). PRMT5        mimicked situation HeLa cells using complex symmetrically dimethylates arginines          22-nt-long duplex small interfering RNAs (siRNAs)
Sm proteins B/Bâ¬˜, D1, D3, enhancing affinity SMN complex (Brahms et al. 2001; Frie-
sen et al. 2001). view  presume interplay SMN PRMT5 complexes oc-
curs coordinated, likely coregulated, steps, SMN itself key player assembly
line.  evidence regulation SMNâ€™s activity kinase recognizes SMN pICln (Grimmler et al. 2005). recent study indicating SMN indispensable formation U snRNPs vivo.
   Despite progress unraveling cellular func-
tions SMN, role U snRNP assembly additional functions assigned SMN (splicing, tran-
scription, axonal transport) convincingly
linked pathology SMA. dedi-
cated efforts aspect asked im-
paired U snRNP assembly, reduced levels SMN,       Figure 1. Reduction SMN levels HeLa cells.   Immu- elicit SMA-like symptoms animal test systems.         noblot analysis SMN fibroblasts healthy individual
                                                             (lanes 1,2) SMA type patient (lanes 3,4), HeLa cells
                                                             subjected RNAi (lanes 5â€“8). micrograms total pro-
Results                                                      tein (lanes 1,3,5â€“8) 5 Âµg (lanes 2,4) analyzed SMN
                                                             protein content. RNAi, extracts cells treated Induced reduction SMN protein HeLa cells               siRNAs complementary SMN (lanes 6,8) nonspecific 
impairs U snRNP assembly                                     trol siRNAs (lanes 5,7) analyzed 48 h (lanes 5,6)                                                              72 h (lanes 7,8) transfection. Lower panels immu- studies carried far aimed depletion    nodetection actin blot. (B) Densitometric quanti- SMN complex cell extracts (Meister et al.           fication relative SMN levels versus actin levels shown 


                                                                                           GENES & DEVELOPMENT             2321
 Winkler et al.


 corresponds positions 183â€“205 human SMN            h RNAi treatment intensely inhibited 
mRNAs. shown Figure 1A B, transfection           forming reaction (Fig. 2A, lanes 4,7). conditions
HeLa cells duplex reduces SMN protein           did affect formation group bands (Fig. 2A,
level âˆ¼60  48 h, compared cells trans-      bands denoted R) contain U1-specific protein
fected control siRNA (Fig. 1A, lanes 5,6). 72    lack Sm core domain (Meister Fischer 2002).
h, expression SMN suppressed âˆ¼22  SMN            Importantly, inhibition assembly observed
protein remaining (Fig. 1A, lanes 7,8). transfection      extracts derived cells RNAi-induced reduc-
efficiency experiments range 95 ,      tion essential splicing factor hPrp4 (Fig. 2B,C).
ruling possibility significant   suggests observed assembly defect extract derived untransfected cells  Supple-     extract derived SMN-deficient cells specific.
mentary Fig. 1). findings showed amounts          findings support idea of SMN protein test adjusted          functional SMN protein cells bottleneck effi-
pathological levels. Cells treated way proceed        cient U snRNP assembly. validate indicatory defects RNAi time        vivo, designed pulse-chase experiments monitor U
course, disappearance SMN nuclear         snRNP synthesis novo. HeLa cells treated 72
structures termed gems, slowed proliferation,        h SMN control siRNAs, followed 1-h pulse
tually apoptosis (Supplementary Fig. 1A; data             [35S]methionine allow labeling nascent
shown).                                                       proteins. Lysates cells subjected    Having RNAi tool hand, applied U          immunoprecipitation using antibody directed
snRNP assembly assay extracts RNAi-treated            cap structure U snRNAs (antibody H20)
HeLa cells. assay based ability HeLa cell   (Bringmann Luhrmann 1986). immunoprecipi-
extract retard radiolabeled U1 snRNA native poly-     tate containing radiolabeled U snRNP proteins acrylamide gel electrophoresis (Meister et al. 2001a).        indicatory novo production U
Consistent previous data, extracts prepared         snRNPs.  comparison autoradiographs
control cells efficiently promoted formation         Coomassie-stained U snRNP proteins (Fig. 2D,
slowly migrating M complex (Fig. 2A, lane 2).         lanes 1,3), identified specific bands immuno-
previously shown complex contains fully         precipitate correspond seven Sm proteins assembled Sm core domain snRNPs (Meister               U1 snRNP-specific proteins 70K, U1A, U1C  Fischer 2002). Consistent  anti-Sm protein      asterisks Fig. 2D; note additional U snRNP-
antibody Y12 retards complex migration (Fig.        specific proteins visible extended exposure
2A, lane 5). Importantly, formation M complex      film). contrast, weaker signals ob- significantly reduced extracts cells     tained immunoprecipitation SMN-deficient treated SMN siRNA duplex 48 h (Fig. 2A,     cell lysates (Fig. 2D, cf. lanes 4 3; upper
lanes 3,6). Extracts prepared cells harvested 72   panel SMN protein deficiency). intense

Figure 2. Induced reduction SMN protein HeLa
cells impairs assembly U snRNPs.   Assay assembly U1 snRNP vitro. [32P]-labeled U1
snRNA (lane 1) incubated RNAi-treated
HeLa cell extracts described Figure 1 (lanes 2â€“7) 30 min, assembly monitored native gel elec-
trophoresis described Meister et al. (2001a). (Lanes
5â€“7) Supershifts antibody Y12 used iden-
tify complexes contain Sm proteins. (B) assay described performed extracts cells treated control siRNAs (lanes 2,4) siRNAs hPrp4 mRNA (lanes 3,5). (C) Immu-
noblot analysis hPrp4 â?¤-actin HeLa cell
extracts used B. (D) Impaired synthesis U snRNPs novo SMN protein reduction. HeLa cells trans-
fected SMN siRNA (lane 4) control siRNA
(lanes 2,3) pulsed [35S]cysteine [35S 
thionine  exchanging growth medium, ex-
tracts prepared. Immunoprecipitations car-
ried anti-RNA cap antibody H20 (lanes 3,4) unrelated antibody (lane 2), precipitated proteins analyzed SDS-PAGE autoradiography. lane 1 Coomassie-stained U snRNP proteins. Upper
panels display immunoblot analyses SMN actin extracts SMN siRNA-treated cells. level SMN protein quantified densitometry shown percentage value relation actin.


2322       GENES & DEVELOPMENT
                                                                                        RNP assembly spinal muscular atrophy



band remaining nonspecific, appears negative control (Fig. 2D, cf. lanes 4 2). Similar severe effects observed cells containing 
termediate levels SMN (Supplementary Fig. 2). 
data RNAi approaches,  analysis extracts vitro pulse-chase study vivo, pro-
vide strong support insufficiency SMN protein
impairs U snRNP assembly human cells.


Purified U snRNPs rescue developmental arrest SMN-deficient Xenopus laevis embryos observed effects SMN deficiency U snRNP
assembly encouraged ask disturbances pathway directly linked degeneration cells. case, able protect SMN-
deficient cells degeneration exogenous
supply U snRNPs. somatic cell lines available SMA patients exhibit dramatic phenotypes suitable approach.  devised RNA-interference strategy developing X.
laevis embryos. SiRNAs complementary X. laevis
SMN mRNA injected blastomeres 
cell-stage embryos. analysis proteins indi-
vidual embryos Western blots (Fig. 3B) revealed sig-
nificant reduction SMN protein (Fig. 3B, cf. lanes 1â€“4 5â€“8). apparent gastrula stages
(probably large maternal pool SMN), indi-
cating injection siRNAs does impair initial phase embryonic development.            Figure 3. SMN Gemin2 essential development
large fraction embryos exhibited developmental arrest     Xenopus embryos.   SiRNAs complementary SMN gastrulation (typically 52  80 ,       Gemin2, nonspecific siRNAs injected X. laevis
pending batch eggs), control embryos       embryos, survival scored gastrula (left column) developed normally (Fig. 3A,C). stage 11, control     neurula (middle right columns). Dead developmentally
                                                             arrested embryos display abnormal outgrowth white cell
RNAi-injected embryos begun close blastoporus,
                                                             mass. (B) Western blot analysis SMN level embryos SMN-deficient embryos failed finish gas-
                                                             treated control (lanes 1â€“4) SMN-siRNAs (lanes 5â€“8) trulation. Instead, detached white cells surrounding     comparison actin levels. Analyses embryos received blastoporus indicated massive developmental defects          coinjection U snRNPs  legend Fig. 4 details)
(Fig. 3A, column). neurula stages, control-     shown lanes 9â€“12. lane represents individual
injected embryos formed neural tube, SMN-          embryo. Relative SMN expression levels estimated den-
deficient embryos survived stage did     sitometry comparison actin levels. (C) Quantification close blastoporus (Fig. 3A, second column).     injection studies shown  Results shown phenotype observed SMN-interacting pro-         siRNA concentrations (2 0.2 ÂµM) different siRNAs
tein Gemin2 targeted. case, 95          target. numbers examined embryos (n) indicated
                                                             row.
injected embryos did proceed develop-
ment gastrulation (Fig. 3A,C). effect dose-dependent, 10-fold lower concentration       end products SMN-mediated assembly path-
siRNAs (0.2 ÂµM) marginal effects develop-        way. addition U1 snRNP-specific proteins 70K,
ment, higher concentration (2 ÂµM) toxic        U1A, U1C, isolate contains subset spe-
(Fig. 3C; data shown).                                   cific proteins U2, U4, U5 snRNPs     asked supplementation purified       indicated Fig. 3A). approach remove
U snRNPs compensate loss SMN         contaminating SMN complex associated U sn-
direct binding partner, Gemin2. approach,        RNPs, particles passed anti-SMN im-
used U snRNPs isolated HeLa        munoaffinity matrix injected nuclear extract X. laevis cells (XTC) H20 anti-m3G     embryos.  SMN detected U
immunoaffinity chromatography elevated ionic              snRNP preparation (Fig. 4A, lanes 6â€“9).
strength (420 mM KCl) (Bringmann Luhrmann                   siRNAs SMN Gemin2, 1 ng 1986). preparation contains Sm core particles    purified human U snRNPs embryo injected.
U1, U2, U4, U5 snRNPs  Fig. 4A Sm proteins       Given approximate volume embryo 0.5â€“1 ÂµL,
B/Bâ¬˜, D1, D2, D3, E, F, G, U snRNAs) reflects    injected roughly corresponds concentra-


                                                                                          GENES & DEVELOPMENT            2323
 Winkler et al.



tion 1â€“2 nM. Strikingly, coinjection efficiently             second control experiment, RNA moiety U
prevented developmental arrest observed embryos               snRNPs digested RNase T1 prior injection
injected siRNAs (Fig. 4B; Fig. 3A                SMN-deficient embryos. seen Figure 4B,  column], B, lanes 9â€“12 knock efficiency).            case developmental arrest prevented
Importantly, rescue dose-dependent injec-              Supplementary Fig. 3 efficiency RNase
tion lower amounts  e., 0.1 ng 0.01 ng U snRNP)           treatment). Taken  data indicate iso- severe effects (Fig. 4C). contrast, injection        lated intact U snRNPs supplied trans effi- isolated U snRNPs se did alter develop-               ciently specifically bypass requirement SMN
ment embryos treated control siRNA (Figs. 3A                 Gemin2 developing embryo.
 row], 4B). data verified purified U
snRNPs isolated Xenopus tissue culture (data                                                                      Gene silencing snRNP assembly pathway
shown).
                                                                     causes motor axon degeneration zebrafish
   controls performed ensure specificity rescue.  siRNAs directed gene             rescue SMN-deficient frog embryos U snRNPs
volved unrelated cellular pathway used                 prompted ask SMA-like motoneuron 
conjunction U snRNP injections. siRNAs ap-                  generation likewise linked U snRNP
plied correspond mRNA sequences                   pathway. case, impaired expression endogenous inhibitors DNA replication termed Gemi-                essential factor sole function assembly U
nin H Geminin L (McGarry 2002). Geminins                     snRNPs rise motoneuron phenotype. unstable inhibitors DNA replication degraded             address issue, used recently described approach metaphase/anaphase transition. agreement                   study motor axon degeneration zebrafish data McGarry (2002), injection siRNAs               (McWhorter et al. 2003). Consistent observa- mRNA caused strong developmental ar-                tions X. laevis, authors study showed rest gastrulation (Fig. 4B). developmental defects            injection antisense Morpholinos SMN ze-
elicited RNAi Geminins H L                   brafish embryos terminates development dose 
qualitatively temporally equivalent silencing             pendent manner (McWhorter et al. 2003). transpar- SMN Gemin2 expression. contrast SMN-                  ency embryos allowed close inspection
Gemin2-deprived embryos,  coinjection U                 neurons, revealing specific defects outgrowth snRNPs did circumvent developmental arrest                pathfinding motoneurons. particularly evi-
embryos treated Geminin siRNAs (Fig. 4B).                  dent lower Morpholino concentrations, sur-




Figure 4. Isolated U snRNPs protect SMN- Gemin2-deficient Xenopus embryos developmental arrest.   Characterization U snRNPs used injection experiments. U snRNP proteins resolved SDS-PAGE analyzed Coomassie
staining (lane 1) silver staining (lanes 3,4). (Lanes 2,5) U snRNAs separated denaturing RNA-gel electrophoresis visualized ethidium bromide staining. U snRNPs passed anti-SMN column prior injection remove residual
SMN protein. Immunoblot analysis SMN-depletion shown lanes 6 8; lanes 7 9 mock depletions. (B) X.
laevis embryos treated injection control siRNA siRNAs directed SMN Gemin2, respectively, purified U snRNPs. control specificity rescue, U snRNPs coinjected embryos siRNAs proteins function does relate U snRNP assembly (Geminins H L). second control, embryos coinjected digested U snRNPs. Quantification embryonic survival stage 13 injection siRNAs  siRNA U snRNPs, siRNA RNase T1-digested U snRNPs. (C) X. laevis embryos coinjected siRNAs SMN Gemin2 increasing amounts U snRNPs. Quantification survival rates shown.


2324       GENES & DEVELOPMENT
                                                                                           RNP assembly spinal muscular atrophy



vival rates embryos improved (McWhorter et al.
2003). adopted approach consistently
observe abnormal morphologies motoneurons expression SMN knocked 16  control level (Fig. 5C, cf. lanes 2 1). Immuno-
histochemistry using znp1 antibody (Melancon et al.
1997) revealed abnormal outgrowth axons cau-
dal primary (CaP) variable primary (VaP) motoneu-
rons, leaving axons truncated errone-
ously branched (Fig. 5 [cf. B D], specifica-
tion examined region). 75  SMN-deficient embryos developed phenotype 31
h post-fertilization (Fig. 5I; Supplementary Table 2),
similar situation described earlier (McWhorter et
al. 2003). Injection control Morpholino significant effect axon length morphology (Fig.
5B  Supplementary Table 2).
   asked similar phenotypes like-
wise observed knocking U snRNP
assembly factors. studies chose (1) Gemin2, major component SMN complex, (2) pICln, Sm protein-binding factor PRMT5 complex
(Meister et al. 2000, 2001b; Friesen et al. 2001). ze-
brafish orthologs human Gemin2 human pICln identified NCBI database exhibit 68 
identity (Gemin2) 67  identity (pICln), respectively. Gemin2- pICln-Morpholino 
jected embryos adjusted sublethal doses, phenotype similar SMN morphants ob-
tained  Fig. 5E  Supplementary Tables 1, 2).
Compared noninjected controls, embryos injected sublethal dose SMN-, Gemin2-, pICln-Mor-
pholinos showed slightly delayed development shortened body axes kinked tails, 
veloped normally  Supplementary Table 2). myo-
tome regions, representing targets motoneuronal         Figure 5. Motoneuron defects zebrafish embryos 
innervation, formed normally embryos (regular         duced expression SMN, Gemin2, pICln.   Lateral view myoD expression embryos injected Mo Ge-            zebrafish embryo 31 h post-fertilization (hpf). Motor axons
min2 [n = 36] Mo pICln [n = 21]) (data shown).          stained znp1 antibody. rectangle marks area  number motoneuronal cell bodies          midtrunk level contains 16 motor axons evalu-
slightly decreased subset injected embryos          ated analyzed embryos. (B,D,F,H) Lateral views trunk
duced number isl2-positive cells 20 em-       regions showing znp1 positive motor axons noninjected (B)
bryos injected Gemin2 Mo 21          SMN (D), Gemin2 (F), pICln (H) Morpholino-injected
                                                               embryos. Arrowheads indicate truncated branched axons. 
pICln). remaining expression morphants Ge-
                                                               set F shows truncated axon embryo different min2 pICln 9  11 , respectively, control          shown F. (C,E,G) Western blot analysis extracts ze-
levels (Fig. 5E,G). observations indicate    brafish treated Morpholino oligonucleotides SMN
duced expression factors proven role    (C, lane 2), Gemin2 (E, lane 2), pICln (G, lane 2). Extracts biogenesis U snRNPs causes motor axon degeneration.         noninjected control embryos shown lane 1. Actin
   results shown encouraged analyze            detected control equal loading relative quantifi- motor axon degeneration prevented             cation respective target protein level.   Quantification coinjection isolated U snRNPs. test pos-       motor axon defects zebrafish embryos knock sibility, SMN-Morpholino injected ze-             SMN, Gemin2, pICln. Embryos bifurcated brafish embryos presence puri-       truncated motor axon scored defective.
fied U snRNPs. observed previously, embryos treated SMN-Morpholino displayed reduced expres-
sion SMN (Fig. 6A, lane 2) erroneously truncated        lates HeLa cells Xenopus equally suitable branched motoneurons (Fig. 6D). Strikingly,          rescue (Fig. 6, cf. E F; Fig. 4A U
motor axon defects efficiently prevented coin-         snRNP composition). motoneurons animals jected U snRNPs (Fig. 6E,F). high degree         received U snRNP injection embryonic stage
evolutionary conservation Sm proteins, U snRNP iso-         developed normally resembled control group 


                                                                                             GENES & DEVELOPMENT              2325
 Winkler et al.



                                                                   fects reduced 80  (n = 25) Gemin2 Morpho-
                                                                   lino-injected embryos 50  (n = 24) embryos simul-
                                                                   taneously coinjected Gemin2 Morpholino hu-
                                                                   man U snRNPs.  SMN- Gemin2-deficient
                                                                   zebrafish develop normal motoneurons, provided U
                                                                   snRNPs supplied trans. animal model                                                                    SMA applied provides evidence vivo                                                                    interference RNP assembly pathway causes
                                                                   motor axon degeneration.


                                                                   Discussion
                                                                   genetics spinal muscular atrophy                                                                    known, search causal links cellular
                                                                   processes disease beginning.                                                                    obstacle endeavor confusing variety func-
                                                                   tions assigned SMN protein.  focused                                                                    understood activity SMN analyzing, live
                                                                   organisms, reduction SMN protein im-
                                                                   pairs U snRNP assembly elicits motor axon
                                                                   degeneration. indications SMN levels af-
                                                                   fect formation U snRNP vivo  (1) low
                                                                   efficiency assembly extracts cells SMN
                                                                   content reduced RNAi pathological lev-

Figure 6. Coinjection U snRNPs SMN Morpholinos pre-
vents motor axon defects zebrafish embryos.   Western blot
analysis SMN levels noninjected control embryos (lanes
1,4) embryos injected SMN Morpholino (lane 2) SMN Morpholino combination isolated U snRNPs X. laevis (lane 3) HeLa cells (lane 5; Fig. 4A Coomassie-stained proteins). Actin levels served loading 
trol relative densitometric quantification levels SMN
levels. (B) Quantification motoneuron defects SMN-
deficient zebrafish embryos treated  exogenous U snRNPs. (Câ€“F) Lateral views zebrafish trunk
regions showing znp1-positive motor axons immunostain-
ing. Motor axon phenotypes control Morpholino-injected em-
bryos (C), SMN-deficient embryos (D), embryos coinjected SMN Morpholino U snRNPs X. laevis (E) HeLa cells (F). Arrowheads indicate truncated branched
axons SMN Morpholino-injected embryos D.


jected standard control Morpholino (Fig. 6, cf. E,F C). evaluated defects caudal primary mo-
toneurons (CaP) statistically relevant number ani-
mals (Fig. 6B) 76.9  motoneurons SMN morphants defective, treatment                Figure 7. Coinjection U snRNPs Gemin2 Morpholinos
U snRNPs reduces number control levels (13 â€“               prevents motor axon defects zebrafish embryos.   Western
31 ). treatment U snRNPs does signifi-              blot analysis Gemin2 levels embryos injected cantly elevate level SMN protein morphants               Morpholino (lane 1), Gemin2 Morpholino (lane 2), Gemin2
(Fig. 6A, cf. lanes 2 3,5), consider unlikely       Morpholino combination isolated human U snRNPs. effect mediated potential trace amounts             Actin levels served loading control relative densito-
                                                                   metric quantification levels Gemin2 levels. (B) Quantifica-
SMN U snRNP preparation. Finally, analyzed
                                                                   tion motor axon defects injected zebrafish embryos. similar strategy rescue Gemin2-
                                                                   (Câ€“F) Lateral views zebrafish trunk regions showing znp1-
deficient zebrafish embryos.  complementation               positive motor axons immunostaining. Motor axon phe- human U snRNPs rescued motor axonal defects                   notypes control embryos (C), Gemin2-deficient embryos (D),
(Fig. 7, cf. D,E C). rescue,  consid-         embryos coinjected Gemin2 Morpholino U
erably efficient observed SMN (cf. Figs. 6B          snRNPs. Arrowheads indicate truncated branched axons 7B). number embryos motor axonal                Gemin2 Morpholino-injected embryos.


2326       GENES & DEVELOPMENT
                                                                                       RNP assembly spinal muscular atrophy



els, (2) impaired synthesis U snRNPs novo         U snRNPs digested RNase T1 cells. Encouraged observation, pro-          failed rescue SMN-deficiency X. laevis embryos.
ceeded animal models showed induced             consider possibility unlikely SMN protein deficiency lethal embryos X. lae-       rescue conferred potential impurities U
vis zebrafish. reduction SMN zebrafish      snRNP preparation. stringent, survival rates improved SMA-          ability U snRNPs prevent degeneration
like degeneration motor axons came light                SMN- Gemin2-deficient motoneurons brings (McWhorter et al. 2003; study).                          unanswered question mind,  does
   findings suggest reduced           reduced expression ubiquitous proteins (SMN snRNP assembly cause SMA, correlation            Gemin2) cause tissue-specific phenotype? second speculative direct correlation         question add  U snRNPs, essen-
motoneuron defects U snRNP insufficiency         tial life cell, compensate phenotype?
established. reasoned data need      pursuit answer, worth discussing accordance postulates:  reduced      disease related RNA metabolism, termed Retinitis
expression U snRNP assembly factor        pigmentosa (RP). Like SMA, RP characterized likewise lead degeneration motor axons. Sec-        tissue-specific degeneration cells, case retinal
ond, developmental defects observed pre-        photoreceptors. loci linked RP, recent
ventable supplementation end product         studies identified mutations integral U pathway;  isolated U snRNPs.                     snRNP components  review, Faustino Cooper
   test insufficient supply U         2003). Presuming mutated proteins inactive,
snRNP assembly factor elicits SMA-like symptoms,           opposed gain function, resulting haploin-
knocked zebrafish expression pICln          sufficiency strikingly similar SMA. Gemin2.  animals showed errone-         makes comparison SMA RP remark-
ous axonal outgrowth seen SMN morphants.            able fact case affected tissue ex- Gemin2 pICln far directly linked      hibits tremendous turnover specific mRNAs. functions SMN axonal transport,           development homeostasis photoreceptors require
splicing catalysis, transcription. case axonal   large quantities opsin (Korenbrot Fernald 1989),
transport, participation Gemin2 ruled       axonal pathfinding motoneurons requires plethora (Jablonka et al. 2001).  worth note     receptors neurotrophins  reviews, Chisholm
Gemin2, like SMN, cytosolic          Tessier-Lavigne 1999; Tear 1999; Beattie 2000). complex mediates U snRNP assembly,         easy envisage cells meet demand nuclear complex. recently provided evidence           proteins splicing encoding pre-mRNAs complex intermediate assembly          inefficient. Faustino Cooper (2003) recently raised
pathway unit different function              hypothesis majority ubiquitously ex-
(Grimmler et al. 2005). functional interplay      pressed pre-mRNAs rapidly spliced tissue-
SMN Gemin2 restricted         specific pre-mRNAs. Thinking line, tissue-
mation U snRNPs. pICln, initial identi-       specific pre-mRNA containing suboptimal splice ele-
fication modulator chloride conductance (Krapi-       ments sensitive low levels vinsky et al. 1994) awaits validation,       splicing factors  reduction proteins
cellular pathway appears common            involved biogenesis U snRNPs  SMA) SMN U snRNP assembly (Pu et al. 1999; Friesen et al.       U snRNP components  RP)  cases,
2001; Meister et al. 2001b; Meister Fischer 2002).        evoke specific phenotype.  silencing expression genes encoding Ge-             Alternatively, inefficient U snRNP assembly min2 pICln presumed specifically affect U        weaken motoneuron disturbance 
snRNP assembly pathway. view consider-            SMN-dependent reaction impair cell cu-
ations, believe reduction SMN leads         mulatively. SMNâ€™s proposed activity axonal transport
impaired U snRNP assembly causes motor            (Jablonka et al. 2001; Rossoll et al. 2003; Zhang et al.
axon defects zebrafish embryos. conclusion         2003) function, SMN-deficient supported genetic studies Drosophila         motoneurons exhibit severe defects pathfinding
lanogaster, showing deficiency U snRNA           (McWhorter et al. 2003; study), process inti-
export factor PHAX induces neuromuscular disorder           mately depends efficient transport (Steward 2002). (G. Matera, pers. comm.).                                     detailed evaluation SMNâ€™s activities 
   second probably striking support          text SMN-deficient cells required address correlation motor axon degeneration U         properly.
snRNP assembly finding purified U snRNPs            intriguing question comes motoneuron
injected Xenopus zebrafish embryos compen-        rescue U snRNPs  time develop-
sate loss SMN Gemin2. U snRNPs rescued         ment SMN-deficiency compensated? Zebrafish SMN- Gemin2-deprived embryos                 motoneurons known pass checkpoints knock-downs directed proteins function       axon projects tissue  review, Beattie
 regulators replication, Geminin H L).      2000). checkpoints occur spatial temporal


                                                                                        GENES & DEVELOPMENT             2327
 Winkler et al.



order involve series cytokines receptor                2000), MANSMA 7 MANSMA 21 zebrafish SMN  kind
proteins presented growth cone axon             gift G. Morris, Robert Jones Agnes Hunt Orthopaedic
 reviews, Tessier-Lavigne Goodman 1996;                 Hospital, Oswestry, UK), affinity-purified rabbit polyclonal
Chisholm Tessier-Lavigne 1999). types                antibodies Xenopus SMN, human pICln human
                                                                    Gemin2, respectively.
â?£-motoneurons sensitive reduction SMN, caudal primary (CaP) variable primary neu-              Transcription U snRNAs vitro reconstitution
rons (VaP), develop zebrafish         U snRNPs
embryo. fate determined end gastrula-
tion,  transformed experimental setup,              U snRNP assembly reactions vitro, U1 snRNA 
                                                                    transcriptionally labeled using [â?£-32P]UTP (3000 Ci/mmol; 
gins hours coinjection anti-
                                                                    ersham) gel-purified described previously (Meister et al.
SMN-Morpholino U snRNPs.  albeit
                                                                    2000). standard reconstitution assay, 25 fmol [32P]-labeled
speculative, favor idea short time           U snRNA incubated 10 ÂµL HeLa cell extract (ad-
frame U snRNP levels critical                justed PBS 2.5 mg total protein/mL) presence velopment. work presented raises                  2.5 pmol unlabeled tRNA 30 min 37Â°C. supershift
question robust compensation SMN                 analyses complex M, Y12 antibody (2 Âµg ascite fluid) ficient phenotype U snRNPs stays time.              added incubation continued 10 min. Samples
end, know rescued SMN morphants survive                mixed 1 volume sample buffer (16  glycerol, 10 31 h post-injection, extends event              mg/mL Heparin, 0.025  bromphenol blue, 0.025  xylene cya- hatching. Future studies way assess             nole) analyzed native RNA gel-electrophoresis 
                                                                    scribed previously (Meister et al. 2001a).
persistence rescue zebrafish ontogen-
esis.
                                                                    Immunoprecipitations
                                                                    Antibodies covalently bound protein G-Sepharose beads
Materials methods                                               (Amersham Biosciences) using dimethylpimelimidate (PIERCE)
                                                                    according manufacturerâ€™s protocol. Immunoprecipita-
                                                                    tions carried incubating extracts immobi-
Cell culture, RNAi, pulse-chase analysis
                                                                    lized antibodies (15 Âµg antibody/20 ÂµL bead volume) 1 h HeLa cells human fibroblasts (Jablonka et al. 2001)        4Â°C. Beads washed times PBS (pH 7.5)/0.01 
cultured complete DMEM (Dulbeccoâ€™s modified Eagleâ€™s           NP-40 proteins extracted phenol, precipitated
dium containing glucose L-glutamin [PAA laboratories],          trichloroacetate, analyzed 12  SDS-PAGE. H20 
10  fetal calf serum [FCS; PAA laboratories], penicillin [100       tibody directed RNA cap structure  kind gift U/mL; Invitrogen], streptomycin (0.1 mg/mL; Invitrogen]).       R. LÃ¼hrmann, Max-Planck-Institute Biophysical Chemistry, RNAi experiments, 22-nt-long RNA duplex corresponding         Gottingen, Germany) used positive control, M5 nucleotides 183â€“205 SMN cDNA generated. Cells         â?£-Flag antibody (Sigma) served negative control. Isolations transfected siRNAs using Oligofectamine reagent           U snRNPs HeLa XTC cells performed (QIAGEN) according manufacturerâ€™s protocol, incu-        described (Bringmann Luhrmann 1986). di-
bated 37Â°C time indicated. pulse-chase studies,      gestion human U snRNPs, preparations incubated
cells washed twice PBS 72 h transfection        overnight 5 Ã— 10âˆ’4 U/ÂµL RNase T1.
incubated 1 h starvation medium (GIBCO-BRL) contain-
ing 10  FCS, 2 mM L-alanyl-L-glutamine, 25 mM HEPES-            Injection X. laevis embryos
KOH (pH 7.4).  [35S]methionine/[35S]cysteine (ProMix;
                                                                    Eggs X. laevis fertilized vitro cultivated Amersham-Biosciences) added 45 min. Cells                                                                     described (Kuhl et al. 1996). cell stage, siRNAs (final
washed PBS incubated 1 h complete
                                                                    concentration 0.2 ÂµM 2 ÂµM, respectively) injected DMEM.
                                                                    cells, combination affinity-purified
                                                                    U snRNPs (final concentration 0.5â€“1 ÂµM; generously provided
Preparation cellular extracts immunoblotting                 R. LÃ¼hrmann). Embryos grown stage 13 1/10
                                                                    MBSH [8.8 mM NaCl, 0.1 mM KCl, 0.24 mM NaHCO3, 0.08 preparation extracts HeLa cells, cells                                                                     mM MgSO4, 0.03 mM Ca(NO3)2, 0.04 mM CaCl2, 1 mM
trypsinized, washed PBS, resuspended lysis buffer (150
                                                                    HEPES pH 7.4] 16Â°C scored survival. Sequences mM NaCl, 1 mM EDTA, 10 mM HEPES Â· KOH pH 7.6, 1.5
                                                                    siRNAs follows (sense strands listed : Xl-SMN #1
mM DTT, 0.5  NP-40, 0.5 U/ÂµL RNAsin [Promega], Complete
                                                                    (5â¬˜-GCAUAUGAUAAAGCAGUGUdTdT-3â¬˜); Xl-SMN #2 (5â¬˜-
protease inhibitor [Roche]), homogenized shearing                                                                     GAGAGCUCUGAAGAAUGAGdTdT-3â¬˜); Xl-Gemin2 #1 (5â¬˜- 26G needle. lysate centrifuged 30 min 16,000g,
                                                                    GCAGCACGUUGUCCUGAUGdTdT-3â¬˜); Xl-Gemin2 #2 (5â¬˜-G supernatant used follow experiments. Ex-
                                                                    UUGCGAAAGAAACAGACCdTdT-3â¬˜); Xl-GemininH #1 (5â¬˜-
tracts Xenopus embryos boiling                                                                     UACCAACAAGAAGCAGAGAdTdT-3â¬˜); Xl-GemininH #2 (5â¬˜-
embryos SDS sample buffer. Zebrafish embryos frozen
                                                                    UCUCUGCUUCUUGUUGGUAdTdT-3â¬˜); Xl-GemininL #1 liquid nitrogen, resuspended lysis buffer, sheared                                                                     (5â¬˜-TCTGCATCTGGGTGCCTTGdTdT-3â¬˜); Xl-GemininL 26G needle. extract separated insoluble matter
                                                                    #2 (5â¬˜-CAAGGCACCCAGAUGCAGAdTdT-3â¬˜). centrifugations 16,000g. protein extract quantified Bradford colorimetry equal
                                                                    Silencing gene expression U snRNP injections
loading SDSâ€“polyacrylamide gels verified immu-
                                                                    zebrafish
noblotting using monoclonal â?£-actin antibody (Sigma). 
tibodies used detection assembly factors 7B10       Zebrafish EST sequences encoding putative orthologs mouse monoclonal antibody human SMN (Meister et al.             Gemin2 (accession nos. CN510554, AI793714) pICln


2328       GENES & DEVELOPMENT
                                                                                                 RNP assembly spinal muscular atrophy


(NM_131424, AAH66713) identified NCBI databases                 RNA 7: 1531â€“1542.
using human sequences queries. NCBI BLAST shows 68                Branscombe, T.L., Frankel, , Lee, J.H., Cook, J.R., Yang, ,
identity 83  similarity Gemin2 67  identity              Pestka, S., Clarke, S. 2001. PRMT5 (Janus kinase-bind-
78  similarity pICln, respectively. ESTs contained         ing protein 1) catalyzes formation symmetric dimeth-
length open reading frames 5â¬˜-UTR sequences               ylarginine residues proteins. J. Biol. Chem. 276: 32971â€“
used designing Morpholino antisense oligonucleotides                32976.
(Gene Tools). Zebrafish embryos injected          Bringmann, P. Luhrmann, R. 1986. Purification indi- cell stage âˆ¼0.5 nL following Morpholino anti-           vidual snRNPs U1, U2, U5 U4/U6 HeLa cells sense oligonucleotide solutions: SMN (5â¬˜-CGACATCTTCTG                   characterization protein constituents. EMBO J. 5:
CACCATTGGC-3â¬˜, 3.1 mg/mL); Gemin2 (5â¬˜-TCAACTCCTC                        3509â€“3516.
GGCGTCTGACTTCAT-3â¬˜, 6.3 mg/mL); pICln (5â¬˜-GGTAA                      Cartegni, L. Krainer, R. 2002. Disruption SF2/ASF-
ACTCTTCAACAGCACCATCC-3â¬˜, 6.3 mg/mL), standard                       dependent exonic splicing enhancer SMN2 causes spinal
control (5â¬˜-CCTCTTACCTCAGTTACAATTTATA-3â¬˜, 6.3 mg/                       muscular atrophy absence SMN1. Nat. Genet. 30:
mL). rescue experiments, SMN Gemin2 Morpholinos                 377â€“384.
(final concentration 3.1 6.3 mg/mL, respectively) coin-     Chisholm,  Tessier-Lavigne, M. 1999. Conservation jected purified Xenopus human U snRNPs (0.1 mg/mL;              divergence axon guidance mechanisms. Curr. Opin. Neu-
provided R. LÃ¼hrmann) described. Following injection,         robiol. 9: 603â€“615.
embryos reared 28Â°C prim-15 stage (30â€“31 h         Faustino, N  Cooper, T  2003. Pre-mRNA splicing post-fertilization)  Kimmel et al. 1995) subjected      human disease. Genes & Dev. 17: 419â€“437. situ hybridizations immunostainings.                          Friesen, W.J., Paushkin, S., Wyce, , Massenet, S., Pesiridis,
                                                                        G.S., Van Duyne, G., Rappsilber, J., Mann, M., Dreyfuss,
                                                                        G. 2001. methylosome, 20S complex containing JBP1
RNA situ hybridizations immunostainings
                                                                        pICln, produces dimethylarginine-modified Sm pro- mount RNA situ hybridizations islet2 expression            teins. Mol. Cell. Biol. 21: 8289â€“8300. motoneurons (Appel et al. 1995) myoD somites (Wein-        Grimmler, M., Bauer, L., Nousiainen, M., Korner, R., Meister,
berg et al. 1996) performed described earlier (Winkler et       G., Fischer, U. 2005. Phosphorylation regulates ac-
al. 2003). mount immunostainings, embryos                tivity SMN complex assembly spliceosomal
fixed overnight 4  paraformaldehyde/PBS/0.1  Tween,               U snRNPs. EMBO Rep. 6: 70â€“76.
chorionated PBS/0.1  Tween, stored methanol.         Gubitz, K., Feng, W., Dreyfuss, G. 2004. SMN com-
rehydration, embryos soaked water 1 h subse-            plex. Exp. Cell Res. 296: 51â€“56.
quently incubated PBDT blocking solution (1  DMSO, 1              Hsieh-Li, H.M., Chang, J.G., Jong, Y.J., Wu, M.H., Wang, N.M.,
BSA, 0.5  Triton X-100, 2.5  goat serum PBS) 1 h.            Tsai, C.H., Li, H. 2000. mouse model spinal mus-
samples incubated znp1 antibody (diluted             cular atrophy. Nat. Genet. 24: 66â€“70.
1:100 PBDT) described Melancon et al. (1997)         Jablonka, S., Bandilla, M., Wiese, S., Buhler, D., Wirth, B., Sendt-
tected using Vectastain Elite kit (Vector Laboratories)        ner, M., Fischer, U. 2001. regulation survival diaminobenzidine chromogenic substrate. znp1 antibody            motor neuron (SMN) protein interactor SIP1 kindly provided Zebrafish International Resource             development spinal muscular atrophy. Hum. Mol.
Center ZIRC (NIH #RR12546). Trunk regions stained em-              Genet. 10: 497â€“505.
bryos manually dissected remaining embryo           Jablonka, S., Holtmann, B., Meister, G., Bandilla, M., Rossoll,
ing razor blades mounted flat 100  glycerol photog-          W., Fischer, U., Sendtner, M. 2002. Gene targeting raphy.                                                                  Gemin2 mice reveals correlation defects                                                                         biogenesis U snRNPs motoneuron cell death. Proc.
                                                                        Natl. Acad. Sci. 99: 10126â€“10131.
Acknowledgments                                                      Kambach, C., Walke, S., Young, R., Avis, J.M., la Fortelle, E.,
                                                                        Raker, V , Luhrmann, R., Li, J., Nagai, K. 1999. Crystal indebted Reinhard LÃ¼hrmann providing purified U
                                                                        structures Sm protein complexes implica-
snRNPs H20 antibody Glenn Morris antibod-
                                                                        tions assembly spliceosomal snRNPs. Cell
ies zebrafish SMN. thank Greg Matera shar-
                                                                        96: 375â€“387.
ing unpublished data, Andreas BrandstÃ¤tter Cordula
                                                                     Kashima, T. Manley, J.L. 2003. negative element Neuner help immunostainings, Ashwin Chari                                                                         SMN2 exon 7 inhibits splicing spinal muscular atrophy.
critical readings manuscript. work funded                                                                         Nat. Genet. 34: 460â€“463.
grants Deutsche Forschungsgemeinschaft (SFB581,
                                                                     Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B., GRK1048, FOR426) Families SMA.
                                                                        Schilling, T.F. 1995. Stages embryonic development                                                                         zebrafish. Dev. Dyn. 203: 253â€“310.
                                                                     Korenbrot, J  Fernald, R.D. 1989. Circadian rhythm References
                                                                        light regulate opsin mRNA rod photoreceptors. Nature
Appel, B., Korzh, V., Glasgow, E., Thor, S., Edlund, T., Dawid,         337: 454â€“457.
   B., Eisen, J.S. 1995. Motoneuron fate specification      Krapivinsky, G.B., Ackerman, M.J., Gordon, E , Krapivinsky,
   vealed patterned LIM homeobox gene expression em-              L.D., Clapham, D.E. 1994. Molecular characterization    bryonic zebrafish. Development 121: 4117â€“4125.                       swelling-induced chloride conductance regulatory protein,
Beattie, C.E. 2000. Control motor axon guidance ze-           pICln. Cell 76: 439â€“448.
   brafish embryo. Brain Res. Bull. 53: 489â€“500.                     Kuhl, M., Finnemann, S., Binder, O., Wedlich, D. 1996.
Brahms, H., Meheus, L., Brabandere, V., Fischer, U.,             Dominant negative expression cytoplasmically deleted
   Luhrmann, R. 2001. Symmetrical dimethylation arginine             mutant XB/U-cadherin disturbs mesoderm migration dur-
   residues spliceosomal Sm protein B/Bâ¬˜ Sm-like             ing gastrulation Xenopus laevis. Mech. Dev. 54: 71â€“82.
   protein LSm4, interaction SMN protein.         Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P.,


                                                                                                   GENES & DEVELOPMENT              2329
 Winkler et al.


    Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani,       110: 537â€“540.
    M., et al. 1995. Identification characterization spinal   Strasswimmer, J., Lorson, C.L., Breiding, D.E., Chen, J.J., Le, T.,
    muscular atrophy-determining gene. Cell 80: 155â€“165.                  Burghes, H., Androphy, E.J. 1999. Identification sur-
Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O.,           vival motor neuron transcriptional activator-binding
    Munnich, , Dreyfuss, G., Melki, J. 1997. Correlation            protein. Hum. Mol. Genet. 8: 1219â€“1226.
    severity SMN protein level spinal muscular          Tear, G. 1999. Neuronal guidance. genetic perspective.
    atrophy. Nat. Genet. 16: 265â€“269.                                     Trends Genet. 15: 113â€“118.
Lorson, C.L. Androphy, E.J. 2000. exonic enhancer            Tessier-Lavigne, M. Goodman, C.S. 1996. molecular
    required inclusion essential exon SMA             biology axon guidance. Science 274: 1123â€“1133.
    termining gene SMN. Hum. Mol. Genet. 9: 259â€“265.                   Weinberg, E.S., Allende, M.L., Kelly, C.S., Abdelhamid, , Mu-
Lorson, C.L., Hahnen, E., Androphy, E.J., Wirth, B. 1999.           rakami, T., Andermann, P., Doerre, O.G., Grunwald, D.J.,
    single nucleotide SMN gene regulates splicing           Riggleman, B. 1996. Developmental regulation ze-
    responsible spinal muscular atrophy. Proc. Natl. Acad.            brafish MyoD wild-type, tail spadetail embryos.
    Sci. 96: 6307â€“6311.                                                   Development 122: 271â€“280.
McGarry, T.J. 2002. Geminin deficiency causes Chk1-depen-             C.L. Luhrmann, R. 2001. Spliceosomal UsnRNP bio-
    dent G2 arrest Xenopus. Mol. Biol. Cell 13: 3662â€“3671.             genesis, structure function. Curr. Opin. Cell Biol.
McWhorter, M.L., Monani, U.R., Burghes, H., Beattie,                13: 290â€“301.
    C.E. 2003. Knockdown survival motor neuron (Smn)            Winkler, C., Schafer, M., Duschl, J., Schartl, M., Volff, J.N.
    protein zebrafish causes defects motor axon outgrowth           2003. Functional divergence zebrafish midkine
    pathfinding. J. Cell Biol. 162: 919â€“931.                          growth factors following fish-specific gene duplication. Ge-
Meister, G. Fischer, U. 2002. Assisted RNP assembly              nome Res. 13: 1067â€“1081.
    purified components: SMN- pICln-complexes cooperate            Zhang, H.L., Pan, F., Hong, D., Shenoy, S.M., Singer, R.H.,     formation spliceosomal U snRNPs. EMBO J.                    Bassell, G.J. 2003. Active transport survival motor
    21: 5853â€“5863.                                                        neuron